Tiragolumab
drug drugOn this page
Also known as Mtig 7192aMTIG-7192AMtig7192aRG-6058RG6058RO-7092284RO7092284
Summary
Tiragolumab (CHEMBL4298050) is a phase-3 clinical-stage antibody; indicated across 21 conditions including neoplasm and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 21 conditions
- Clinical trials: 62
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298050 |
| Name | Tiragolumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Mtig 7192a, MTIG-7192A, Mtig7192a, MTIG7192A, RG-6058, RG6058, RO-7092284, RO7092284, Tiragolumab, TIRAGOLUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
17 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| small cell lung carcinoma | 3 | MONDO:0008433 | EFO:0000702 |
| carcinoma of esophagus | 3 | MONDO:0019086 | EFO:0002916 |
| esophageal squamous cell carcinoma | 3 | MONDO:0005580 | EFO:0005922 |
| hepatocellular carcinoma | 3 | MONDO:0007256 | EFO:0000182 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| rectal cancer | 2 | MONDO:0006519 | EFO:1000657 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| renal cell adenocarcinoma | 2 | MONDO:0005549 | EFO:0005708 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| gastric adenocarcinoma | 1 | MONDO:0005036 | EFO:0000503 |
| urothelial carcinoma | 1 | MONDO:0040679 | EFO:0008528 |
| triple-negative breast carcinoma | 1 | MONDO:0005494 | EFO:0005537 |
| endometrium neoplasm | 1 | MONDO:0021251 | MONDO:0011962 |
| adenocarcinoma | 1 | MONDO:0004970 | MONDO:0003219 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 62.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 32 |
| PHASE1/PHASE2 | 14 |
| PHASE3 | 9 |
| PHASE1 | 6 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04543617 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy |
| NCT04665856 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT05862285 | PHASE3 | RECRUITING | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study |
| NCT05904886 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) |
| NCT04256421 | PHASE3 | COMPLETED | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT04294810 | PHASE3 | COMPLETED | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer |
| NCT04513925 | PHASE3 | COMPLETED | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
| NCT04540211 | PHASE3 | COMPLETED | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma |
| NCT04619797 | PHASE2/PHASE3 | COMPLETED | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer |
| NCT06267001 | PHASE3 | COMPLETED | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy |
| NCT03708224 | PHASE2 | RECRUITING | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck |
| NCT03784326 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma |
| NCT04486352 | PHASE1/PHASE2 | RECRUITING | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer |
| NCT04524871 | PHASE1/PHASE2 | RECRUITING | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) |
| NCT04958811 | PHASE2 | ACTIVE_NOT_RECRUITING | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC |
| NCT05009069 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer |
| NCT05286801 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
| NCT05394337 | PHASE1/PHASE2 | RECRUITING | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma |
| NCT05483400 | PHASE2 | RECRUITING | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors |
| NCT05645692 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer |
| NCT05681039 | PHASE2 | RECRUITING | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). |
| NCT05715281 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial |
| NCT05798663 | PHASE2 | ACTIVE_NOT_RECRUITING | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC |
| NCT05805501 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma |
| NCT05825625 | PHASE2 | ACTIVE_NOT_RECRUITING | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing |
| NCT06003621 | PHASE2 | RECRUITING | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients |
| NCT06342037 | PHASE2 | RECRUITING | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial |
| NCT06754501 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary |
| NCT06784947 | PHASE2 | ACTIVE_NOT_RECRUITING | Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer |
| NCT03193190 | PHASE1/PHASE2 | COMPLETED | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) |
| NCT03281369 | PHASE1/PHASE2 | COMPLETED | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) |
| NCT03337698 | PHASE1/PHASE2 | TERMINATED | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) |
| NCT03554083 | PHASE2 | COMPLETED | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma |
| NCT03563716 | PHASE2 | COMPLETED | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT03869190 | PHASE1/PHASE2 | COMPLETED | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) |
| NCT03977467 | PHASE2 | COMPLETED | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor |
| NCT04300647 | PHASE2 | COMPLETED | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer |
| NCT04308785 | PHASE2 | TERMINATED | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer |
| NCT04632992 | PHASE2 | COMPLETED | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response |
| NCT04665843 | PHASE2 | COMPLETED | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck |
| NCT04832854 | PHASE2 | TERMINATED | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer |
| NCT04933227 | PHASE2 | TERMINATED | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) |
| NCT05034055 | PHASE2 | UNKNOWN | Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer |
| NCT05060003 | PHASE2 | TERMINATED | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection |
| NCT05116202 | PHASE1/PHASE2 | COMPLETED | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) |
| NCT05251948 | PHASE1/PHASE2 | TERMINATED | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma |
| NCT05315713 | PHASE1/PHASE2 | TERMINATED | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma |
| NCT05459129 | PHASE1/PHASE2 | COMPLETED | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) |
| NCT05661578 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors |
| NCT05743504 | PHASE1/PHASE2 | UNKNOWN | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients |
| NCT05746481 | PHASE2 | TERMINATED | Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases |
| NCT05908786 | PHASE1/PHASE2 | COMPLETED | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma |
| NCT06328036 | PHASE2 | WITHDRAWN | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma |
| NCT06331598 | PHASE2 | WITHDRAWN | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) |
| NCT06603818 | PHASE2 | WITHDRAWN | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) |
| NCT07038915 | PHASE2 | WITHDRAWN | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 |
| NCT04929223 | PHASE1 | RECRUITING | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) |
| NCT06760481 | PHASE1 | ACTIVE_NOT_RECRUITING | Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) |
| NCT02794571 | PHASE1 | COMPLETED | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors |
| NCT04045028 | PHASE1 | TERMINATED | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT04584112 | PHASE1 | COMPLETED | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer |
| NCT05259319 | PHASE1 | UNKNOWN | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).